Bionano reports Q3 2026 revenue up 12% on reimbursement and publication progress
The company cited OGM reimbursement and state approval steps and three new studies while reiterating 2026 revenue guidance of $31 to $33 million.
SEC filing
Latest
2 stories
Yesterday
Tuesday, October 27
Bionano Genomics files S-1 to register 1.3 million warrant shares
The San Diego genomics company registered shares underlying four outstanding warrant series after its prior Form S-3 shelf nears expiration on November 6, 2026.
SEC filing